BACKGROUND: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma.
Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority.
CASE REPORT: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor.
CONCLUSION: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.
Gambini D, Locatelli E, Gianelli U, Bareggi C, Galassi B, Visintin R, Massironi S, Dell'orto PG, Tomirotti M. Are you the author?
Unit of Medical Oncology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy; Hematopathology Section, Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan School of Medicine, Milan, Italy; Unit of Gastroenterology and Endoscopy, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy; Urology Unit, Clinical Surgery I, University Milan School of Medicine, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy.
Reference: Anticancer Res. 2014 Dec;34(12):7361-5.